Tech Company Financing Transactions
Beta Bionics Funding Round
Beta Bionics, based in Boston, raised $100 million in investment from Omega Funds, Sands Capital Management and ArrowMark Partners.
Transaction Overview
Company Name
Announced On
9/1/2023
Transaction Type
Venture Equity
Amount
$100,000,000
Round
Series D
Investors
Omega Funds (Lead Investor)
Sands Capital Management (Lead Investor)
ArrowMark Partners (Tuan Huynh)
Proceeds Purpose
The company intends to use the funds to expand operations and its development efforts.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
8 Saint Mary's St. 936
Boston, MA 02215
USA
Boston, MA 02215
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Beta Bionics is proud to be a Massachusetts public benefit corporation. We believe we are one of the first, if not the first medical device company to be doing business as a benefit corporation, and we're fairly certain that Beta Bionics is the first company to do so in the diabetes space.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Edward Damiano
Vice President
Firas El-Khatib
VP - Bus. Development
Ed Raskin
VP - General Counsel
Serafina Raskin
VP - Operations
David Henderson
VP - R & D
Michael Rosinko
Browse more venture capital transactions:
Prev: 9/1/2023: NT-Tao venture capital transaction
Next: 9/1/2023: Superframe venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. VC investment data records on this site are derived from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs